Chromadex Corp (NASDAQ:CDXC) shares passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $4.27 and traded as low as $4.63. Chromadex shares last traded at $4.69, with a volume of 74,433 shares changing hands.

A number of research analysts have commented on the company. BidaskClub cut Zebra Technologies from a “hold” rating to a “sell” rating in a research note on Friday, May 24th. HC Wainwright set a $55.00 price target on Acer Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, May 28th. Finally, Zacks Investment Research cut Haynes International from a “hold” rating to a “sell” rating in a research note on Wednesday, May 8th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $6.00.

The company has a quick ratio of 1.68, a current ratio of 2.24 and a debt-to-equity ratio of 0.07. The business has a 50 day simple moving average of $4.29. The stock has a market cap of $258.17 million, a P/E ratio of -7.62 and a beta of 1.26.

Chromadex (NASDAQ:CDXC) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.04). Chromadex had a negative return on equity of 108.84% and a negative net margin of 94.78%. The firm had revenue of $10.05 million for the quarter, compared to analyst estimates of $9.80 million. Research analysts predict that Chromadex Corp will post -0.46 EPS for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in the business. Tieton Capital Management LLC lifted its stake in shares of Chromadex by 15.1% in the 1st quarter. Tieton Capital Management LLC now owns 1,257,890 shares of the company’s stock valued at $5,271,000 after purchasing an additional 165,425 shares during the last quarter. Northern Trust Corp lifted its position in Chromadex by 1.2% during the 4th quarter. Northern Trust Corp now owns 411,436 shares of the company’s stock worth $1,412,000 after acquiring an additional 5,009 shares during the last quarter. Geode Capital Management LLC lifted its position in Chromadex by 5.3% during the 4th quarter. Geode Capital Management LLC now owns 346,723 shares of the company’s stock worth $1,189,000 after acquiring an additional 17,361 shares during the last quarter. Granite Investment Partners LLC lifted its position in Chromadex by 87.7% during the 1st quarter. Granite Investment Partners LLC now owns 167,689 shares of the company’s stock worth $702,000 after acquiring an additional 78,373 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in Chromadex by 23.4% during the 4th quarter. Bank of New York Mellon Corp now owns 128,810 shares of the company’s stock worth $442,000 after acquiring an additional 24,408 shares during the last quarter. Institutional investors own 18.08% of the company’s stock.

Chromadex Company Profile (NASDAQ:CDXC)

ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function.

Recommended Story: Percentage Decliners

Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.